ArticleJournal of cheminformatics2026
MINERVA: a public XAI-powered platform advancing multi-target discovery in Alzheimer's disease.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder involving a complex interplay of interconnected pharmacological targets, a feature that limits the success of traditional single-target medicinal chemistry approaches. Here, we present MINERVA (Multi-target Interactive Network for Explainable Research and Visualization in Alzheimer's disease), a public web-based platform designed to support multi-target drug discovery assisted by eXplainable Artificial Intelligence (XAI) strategies. MINERVA integrates large-scale disease-focused high-quality data comprising as many as 70,960 small molecules annotated across 33 AD relevant targets, taken from ChEMBL and CADRO databases. To capture different levels of pharmacological relevance, four distinct pharmacological thresholds (i.e., 10 μM, 1 μM, 100 nM, and 10 nM) were set to enable the parallel exploration of weak to high-affinity ligand spaces. Independent Balanced Random Forest (BRF) classifiers were trained for each AD target threshold combination using an extended core-substituent fingerprint, which ensures robustness against class imbalance and chemical heterogeneity. MINERVA incorporates a probability binning based domain of applicability (DoA) to quantify prediction reliability and a SHAP-based explainability framework to fairly map fragment-level contributions directly onto chemical structures. MINERVA is freely accessible at https://prometheus.farmacia.uniba.it/minerva/ .Scientific contributionHerein we introduce MINERVA, the first freely accessible platform that combines large-scale AD-related data curation, multi-target prediction, and multi-threshold bioactivity modeling within a fully explainable and user-friendly environment. By enabling transparent, ligand-based exploration of chemical space across multiple AD pathways, MINERVA provides a unique and practical resource for accelerating multi-target drug discovery in the neurodegenerative research area.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.